From Medscape Gastroenterology

The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD)

November 04 - 08, 2022; Washington, DC/Virtual

November 04 - 08, 2022 Washington, DC/Virtual

AASLD 2022 Bepirovirsen: Is a 'Functional Cure' for HBV on the Horizon? The potential first-in-class antisense RNA-based therapy led to sustained clearance of HBsAg and HBV DNA for 24 weeks after treatment ended in the phase 2b study.
Medscape Medical News, November 17, 2022
AASLD 2022 Steroids, G-CSF Up 90-day Survival in Severe Alcoholic Hepatitis Patients with severe alcoholic hepatitis who received the combination had better 90-day survival and fewer infections compared with those who received either drug alone.
Medscape Medical News, November 9, 2022
AASLD 2022 Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis After 1 year of therapy with the oral thyromimetic, patients with well-compensated NASH cirrhosis had significant improvements in both liver- and heart-related risk factors.
Medscape Medical News, November 7, 2022

Medscape Gastroenterology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.